The most recent earnings reports show CTXR narrowing its quarterly losses, which strengthens the "ctxr stock forecast 2025" outlook. If sales from its lead antibiotic candidate hit projected $15M in early 2025, market sentiment could shift bullish, with possible resistance around $1.45 and a breakout target near $1.70. H.C. Wainwright initiated coverage of Arcutis Biotherapeutics (ARQT) with a Buy rating and $19 price target. The firm expects Zoryve, across its family of strengths and presentations, to become one of the leading topical agents for treating inflammatory dermatology conditions including psoriasis, atopic dermatitis, and seborrheic dermatitis with "blockbuster" peak sales potential. Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. Data from biotech benchmarks show CTXR aligning with growth median values, keeping the "ctxr stock forecast 2025" at a steady bullish bias. CAPM analysis suggests an expected annual return of 14% with current beta levels.